Study Summary
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Want to learn more about this trial?
Request More InfoInterventions
Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20BIOLOGICAL
Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Children's Hospital | Shenzhen | Guangdong | China |
| The Seventh Affilliated Hospital, Sun Yat-Sen University | Shenzhen | Guangdong | China |
| Shijiazhuang Zhongxi Children Hospital | Shijiazhuang | Hebei | China |